Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Shares Outstanding (Weighted Average) (2016 - 2025)

Abeona Therapeutics (ABEO) has 14 years of Shares Outstanding (Weighted Average) data on record, last reported at $54.2 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 12.81% year-over-year to $54.2 million; the TTM value through Sep 2025 reached $54.2 million, up 12.81%, while the annual FY2024 figure was $41.0 million, 91.99% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $54.2 million in Q3 2025 per ABEO's latest filing, up from $52.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $94.2 million in Q1 2021 and bottomed at $3.9 million in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $27.7 million, with a median of $21.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 95.83% in 2021, then surged 312.61% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $3.9 million in 2021, then surged by 99.65% to $7.9 million in 2022, then skyrocketed by 171.96% to $21.4 million in 2023, then surged by 91.99% to $41.0 million in 2024, then surged by 32.14% to $54.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $54.2 million in Q3 2025, $52.5 million in Q2 2025, and $49.8 million in Q1 2025.